ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 154 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,423 | -53.1% | 48,391 | -33.5% | 0.00% | -50.0% |
| Q2 2023 | $101,178 | +3.2% | 72,790 | +398.7% | 0.00% | -33.3% |
| Q3 2022 | $98,000 | +55.6% | 14,596 | +15.8% | 0.01% | +100.0% |
| Q4 2021 | $63,000 | -91.4% | 12,603 | -79.3% | 0.00% | -92.9% |
| Q3 2021 | $734,000 | -8.1% | 60,927 | +61.3% | 0.04% | -17.6% |
| Q2 2021 | $799,000 | -13.4% | 37,776 | +14.8% | 0.05% | +10.9% |
| Q1 2021 | $923,000 | +8.5% | 32,912 | +0.6% | 0.05% | +24.3% |
| Q4 2020 | $851,000 | +87.9% | 32,713 | +270.9% | 0.04% | +60.9% |
| Q2 2020 | $453,000 | +15.9% | 8,820 | +5.0% | 0.02% | +4.5% |
| Q2 2019 | $391,000 | – | 8,399 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |